Marksans Pharma Limited

BSE: 524404 NSE: MARKSANS
Marksans Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24110MH1992PLC066364 Incorporated 16 April 1992 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: MARKSANS · BSE: 524404 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹2,950.94 Cr
▲ 1025.09% YoY
Computed EBITDA · FY 2026
₹683.31 Cr
▲ 1040.73% YoY
Net profit · FY 2026
₹420.06 Cr
▲ 997.86% YoY
Authorised capital
₹69 Cr
Registered with MCA
Paid-up capital
₹45.32 Cr
Issued & subscribed
Open charges
₹226 Cr
Satisfied ₹337.16 Cr
Company age
34 yrs
Est. 1992
Employees · EPFO
95
Latest available

About Marksans Pharma Limited

Data last updated: 15 July 2026

Marksans Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 16 April 1992, the company has been in operation for over 34 years.

Registered with ROC Mumbai under CIN L24110MH1992PLC066364. Listed on BSE: 524404 and NSE: MARKSANS.

Capital: an authorised share capital of ₹69 Cr and a paid-up capital of ₹45.32 Cr. Formerly known as Tasc Pharmaceuticals Limited and Tasc Industries (India) Limited. It is led by directors including Sandra Saldanha and Varddhman Vikramaditya Jain.

Last AGM: 08 August 2025. Financial statements filed for year ended 31 March 2025. Office: 11Th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri (W), Mumbai, Maharashtra, India – 400053.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹2,950.94 Cr, reflecting significant growth compared to the previous year. The net worth stands at ₹3,052.68 Cr (up 1126.28% YoY). Total assets are valued at ₹3,860.9 Cr (up 1091.77% YoY).

The company has a workforce of approximately 95 employees as per the latest available data.

The company is associated with 1 brand - Marksans Pharma. As per MCA filings, the company has open charges of ₹226 Cr and satisfied charges of ₹337.16 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website marksanspharma.com.

Company Details of Marksans Pharma Limited
CIN L24110MH1992PLC066364
Registration Number 066364
Incorporation Date 16 April 1992
ROC Mumbai
Listing Status Listed (BSE: 524404, NSE: MARKSANS)
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Mark Saldanha Managing Director Sandra Saldanha Whole-Time Director Varddhman Vikramaditya Jain Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    marksanspharma.com
  • Social Media
  • Registered Address
    11Th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri (W), Mumbai, Maharashtra, India – 400053
  • Industry
    Pharma, Drug Formulation & Development
Company report
Marksans Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Marksans Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Marksans Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Marksans Pharma Limited

Marksans Pharma Limited has undergone 2 name changes throughout its history. The company was previously known as Tasc Pharmaceuticals Limited, and Tasc Industries (India) Limited. The current legal name is Marksans Pharma Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Marksans Pharma Limited Current
Tasc Pharmaceuticals Limited Previous
Tasc Industries (India) Limited Previous

Associated Brands with Marksans Pharma Limited

Marksans Pharma Limited operates one associated brand: Marksans Pharma. These brands represent Marksans Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Marksans Pharma
Pharmaceutical drug formulations are manufactured, developed, and marketed. marksanspharma.com

Business Activity of Marksans Pharma Limited

Marksans Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Marksans Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Marksans Pharma Limited

Marksans Pharma Limited is audited by MSKA & Associates LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
MSKA & Associates LLP (ICAI peer reviewed, certificate valid till 2027-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Marksans Pharma Limited

Marksans Pharma Limited is currently managed by 8 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Sandra Saldanha Whole-Time Director 25 Sep 2014 11 Years 10 Months Current
Varddhman Vikramaditya Jain Whole-Time Director 24 Jan 2019 7 Years 6 Months Current
Abhinna Mohanty Sundar
Also directs: Rytus Healthcare Private Limited, Ssb Seva Kartavya Private Limited
Director 11 Jul 2019 7 Years 1 Months Current
Mark Saldanha Managing Director 06 Oct 2015 10 Years 10 Months Current
Digant Mahesh Parikh
Also directs: Rossell Techsys Limited, Akansha Consultancy Services Limited
Director 14 Mar 2018 8 Years 4 Months Current
Sunny Sharma
Also directs: Advanced Enzyme Technologies Limited, Arcatron Mobility Private Limited, Lattice Medtech Private Limited and 5 more
Director 11 Aug 2021 5 Years 0 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Marksans Pharma Limited FY 2026 filings available

Marksans Pharma Limited reported revenue of ₹2,950.94 Cr (up 1025.09% YoY) for FY 2026.

Revenue · FY 2026
₹2,950.94 Cr ▲ 1025.09%
Profit · FY 2026
₹420.06 Cr ▲ 997.86%
Computed EBITDA · FY 2026
₹683.31 Cr ▲ 1040.73%
Revenue₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹1,134 Cr1,134FY 2020FY 2021: ₹1,376 Cr · +21.3% YoY1,376+21.3%FY 2021FY 2022: ₹1,491 Cr · +8.3% YoY1,491+8.3%FY 2022FY 2023: ₹1,852 Cr · +24.2% YoY1,852+24.2%FY 2023FY 2024: ₹2,177 Cr · +17.6% YoY2,177+17.6%FY 2024FY 2025: ₹262 Cr · -88% YoY262-88%FY 2025FY 2026: ₹2,951 Cr · +1025.1% YoY2,951+1025.1%FY 2026
Net Profit₹ Cr · Consolidated0200400600FY 2020: ₹121 Cr121FY 2020FY 2021: ₹239 Cr · +97.5% YoY239+97.5%FY 2021FY 2022: ₹187 Cr · -21.7% YoY187-21.7%FY 2022FY 2023: ₹265 Cr · +42% YoY265+42%FY 2023FY 2024: ₹315 Cr · +18.7% YoY315+18.7%FY 2024FY 2025: ₹38 Cr · -87.8% YoY38.3-87.8%FY 2025FY 2026: ₹420 Cr · +997.9% YoY420+997.9%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,000Q1'25: ₹591 Cr · +18.1% YoY591+18.1%Q1'25Q2'25: ₹642 Cr · +20.8% YoY642+20.8%Q2'25Q3'25: ₹682 Cr · +16.3% YoY682+16.3%Q3'25Q4'25: ₹71 Cr · -87.3% YoY70.8-87.3%Q4'25Q1'26: ₹620 Cr · +5% YoY620+5%Q1'26Q2'26: ₹720 Cr · +12.2% YoY720+12.2%Q2'26Q3'26: ₹754 Cr · +10.6% YoY754+10.6%Q3'26Q4'26: ₹856 Cr · +1108.4% YoY856+1108.4%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,950.94 Cr ₹262.28 Cr ₹2,177.41 Cr ₹1,852.14 Cr ₹1,490.84 Cr ₹1,376.18 Cr ₹1,134.21 Cr
Other Income ₹82.53 Cr ₹7.04 Cr ₹50.42 Cr ₹59.31 Cr ₹41.85 Cr ₹6.69 Cr ₹32.8 Lakh
Total Income ₹3,033.47 Cr ₹269.32 Cr ₹2,227.83 Cr ₹1,911.45 Cr ₹1,532.69 Cr ₹1,382.88 Cr ₹1,134.54 Cr
Cost of Materials Consumed ₹959.21 Cr ₹75.3 Cr ₹667.7 Cr ₹612.97 Cr ₹540.67 Cr ₹419.76 Cr ₹371.33 Cr
Purchases of Stock-in-Trade ₹454.49 Cr ₹57.45 Cr ₹444.28 Cr ₹314.78 Cr ₹163.25 Cr ₹311.57 Cr ₹120.6 Cr
Changes in Inventories -₹136.42 Cr -₹18.38 Cr -₹73.86 Cr -₹6.39 Cr ₹12.9 Cr -₹136.28 Cr ₹52.95 Cr
Employee Benefit Expense ₹420.93 Cr ₹35.03 Cr ₹293.64 Cr ₹239.37 Cr ₹220.3 Cr ₹197.32 Cr ₹168.42 Cr
Finance Costs ₹24.13 Cr ₹1.17 Cr ₹11.2 Cr ₹9.13 Cr ₹8.45 Cr ₹7.99 Cr ₹8.75 Cr
Depreciation & Amortisation ₹98.63 Cr ₹8.34 Cr ₹74.27 Cr ₹51.85 Cr ₹44.78 Cr ₹36.15 Cr ₹26.66 Cr
Other Expenses ₹651.95 Cr ₹60.02 Cr ₹387.07 Cr ₹352.09 Cr ₹294.84 Cr ₹244.2 Cr ₹228.66 Cr
Total Expenses ₹2,472.92 Cr ₹218.93 Cr ₹1,804.3 Cr ₹1,573.8 Cr ₹1,285.18 Cr ₹1,080.71 Cr ₹977.36 Cr
Profit Before Exceptional Items & Tax ₹560.56 Cr ₹50.4 Cr ₹423.53 Cr ₹337.65 Cr ₹247.51 Cr ₹302.16 Cr ₹157.17 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹560.56 Cr ₹50.4 Cr ₹423.53 Cr ₹337.65 Cr ₹247.51 Cr ₹302.16 Cr ₹157.17 Cr
Total Tax Expense ₹140.49 Cr ₹12.13 Cr ₹108.63 Cr ₹72.33 Cr ₹60.7 Cr ₹63.63 Cr ₹36.42 Cr
Net Profit ₹420.06 Cr ₹38.26 Cr ₹314.9 Cr ₹265.32 Cr ₹186.81 Cr ₹238.54 Cr ₹120.75 Cr
  attributable to Owners ₹417.9 Cr ₹0 ₹342.55 Cr - - - -
  attributable to NCI ₹2.16 Cr ₹0 ₹94.2 Lakh - - - -
Other Comprehensive Income ₹176.15 Cr ₹4.8 Cr ₹28.6 Cr ₹52.21 Cr ₹50.28 Cr ₹46.8 Lakh ₹6.56 Cr
Total Comprehensive Income ₹596.21 Cr ₹43.07 Cr ₹343.49 Cr ₹317.53 Cr ₹237.1 Cr ₹239.01 Cr ₹127.32 Cr
EBITDA (computed) ₹683.31 Cr ₹59.9 Cr ₹509 Cr ₹398.63 Cr ₹300.73 Cr ₹346.3 Cr ₹192.58 Cr
Basic EPS ₹9.22 ₹8.40 ₹6.92 ₹6.41 ₹4.51 ₹5.76 ₹2.86
Diluted EPS ₹9.22 ₹8.40 ₹6.92 ₹6.41 ₹4.51 ₹5.76 ₹2.86
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹3,860.9 Cr ₹323.96 Cr ₹2,680.95 Cr ₹2,190.39 Cr
Non-current Assets ₹1,138.16 Cr ₹103.55 Cr ₹818.46 Cr ₹515.09 Cr
Current Assets ₹2,722.74 Cr ₹220.41 Cr ₹1,862.49 Cr ₹1,675.3 Cr
Property, Plant & Equipment ₹625.01 Cr ₹57.95 Cr ₹675.71 Cr ₹379.64 Cr
Inventories ₹972.28 Cr ₹84.55 Cr ₹617.94 Cr ₹484.74 Cr
Trade Receivables ₹644.57 Cr ₹54 Cr ₹453.18 Cr ₹416.85 Cr
Cash & Equivalents ₹634.14 Cr ₹49.58 Cr ₹403.28 Cr ₹382.44 Cr
Equity (Net Worth) ₹3,052.68 Cr ₹248.94 Cr ₹2,085.91 Cr ₹1,765.07 Cr
Equity Share Capital ₹45.32 Cr ₹4.53 Cr ₹45.32 Cr ₹45.32 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹29.59 Cr ₹2.31 Cr ₹29.09 Cr ₹41.59 Cr
Total Debt (computed) ₹29.59 Cr ₹2.31 Cr ₹29.09 Cr ₹41.59 Cr
Current Liabilities ₹527.09 Cr ₹47.73 Cr ₹389.85 Cr ₹340.99 Cr
Total Liabilities ₹808.22 Cr ₹75.03 Cr ₹595.05 Cr ₹425.32 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹458.13 Cr ₹20.67 Cr ₹230.41 Cr ₹237.41 Cr ₹99.26 Cr
Investing Cash Flow -₹248.27 Cr -₹4.9 Cr -₹140.84 Cr -₹259.21 Cr -₹41.69 Cr
Financing Cash Flow -₹70.93 Cr -₹6.51 Cr -₹68.73 Cr ₹197.83 Cr ₹79.51 Cr
Capital Expenditure ₹130.53 Cr ₹17.29 Cr ₹208.84 Cr ₹53.63 Cr ₹46.33 Cr
Free Cash Flow (computed) ₹327.6 Cr ₹3.37 Cr ₹21.57 Cr ₹183.78 Cr ₹52.93 Cr
Dividends Paid ₹36.25 Cr ₹2.96 Cr ₹22.66 Cr ₹10.17 Cr ₹10.58 Cr
Net Change in Cash ₹138.35 Cr ₹9.25 Cr ₹20.84 Cr ₹176.03 Cr ₹137.08 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹856.11 Cr ₹754.43 Cr ₹720.41 Cr ₹619.99 Cr ₹70.85 Cr ₹681.85 Cr ₹641.92 Cr ₹590.62 Cr ₹560.01 Cr ₹586.13 Cr ₹531.24 Cr ₹500.03 Cr
Other Income ₹35.17 Cr ₹20.14 Cr ₹21.57 Cr ₹5.64 Cr ₹1.65 Cr ₹27.85 Cr ₹11.06 Cr ₹14.95 Cr ₹16.53 Cr ₹4.8 Cr ₹19 Cr ₹10.1 Cr
Total Income ₹891.29 Cr ₹774.57 Cr ₹741.98 Cr ₹625.63 Cr ₹72.5 Cr ₹709.7 Cr ₹652.98 Cr ₹605.57 Cr ₹576.54 Cr ₹590.93 Cr ₹550.23 Cr ₹510.13 Cr
Cost of Materials Consumed ₹264.97 Cr ₹273.82 Cr ₹227.72 Cr ₹192.69 Cr ₹18.81 Cr ₹189.26 Cr ₹214.39 Cr ₹161.31 Cr ₹148.38 Cr ₹192.87 Cr ₹174.7 Cr ₹151.76 Cr
Purchases of Stock-in-Trade ₹149.81 Cr ₹26.99 Cr ₹106.14 Cr ₹171.55 Cr ₹16.1 Cr ₹111.95 Cr ₹134.32 Cr ₹167.24 Cr ₹162.98 Cr ₹81.31 Cr ₹85.29 Cr ₹114.71 Cr
Changes in Inventories -₹24.13 Cr ₹15.41 Cr -₹25.27 Cr -₹102.43 Cr -₹2.38 Cr -₹2.87 Cr -₹90.31 Cr -₹66.76 Cr -₹41.53 Cr -₹1.36 Cr -₹7.27 Cr -₹23.71 Cr
Employee Benefit Expense ₹106.76 Cr ₹111.99 Cr ₹103.8 Cr ₹98.39 Cr ₹9.72 Cr ₹88.44 Cr ₹84.16 Cr ₹80.48 Cr ₹79.75 Cr ₹74.53 Cr ₹71.13 Cr ₹68.24 Cr
Finance Costs ₹6.31 Cr ₹5.94 Cr ₹5.82 Cr ₹6.07 Cr ₹34.35 Lakh ₹2.67 Cr ₹2.63 Cr ₹2.92 Cr ₹4.84 Cr ₹3.16 Cr ₹1.63 Cr ₹1.58 Cr
Depreciation & Amortisation ₹24.29 Cr ₹24.33 Cr ₹26.92 Cr ₹23.1 Cr ₹2.27 Cr ₹20.69 Cr ₹19.51 Cr ₹20.44 Cr ₹21.06 Cr ₹22 Cr ₹17.55 Cr ₹13.66 Cr
Other Expenses ₹163.28 Cr ₹165.47 Cr ₹163.52 Cr ₹159.67 Cr ₹16.03 Cr ₹156.3 Cr ₹163.69 Cr ₹119.92 Cr ₹100.8 Cr ₹105.76 Cr ₹93.44 Cr ₹87.07 Cr
Total Expenses ₹691.29 Cr ₹623.95 Cr ₹608.65 Cr ₹549.03 Cr ₹60.89 Cr ₹566.44 Cr ₹528.39 Cr ₹485.55 Cr ₹476.27 Cr ₹478.27 Cr ₹436.46 Cr ₹413.3 Cr
Profit Before Exceptional Items & Tax ₹200 Cr ₹150.62 Cr ₹133.33 Cr ₹76.6 Cr ₹11.61 Cr ₹143.26 Cr ₹124.6 Cr ₹120.02 Cr ₹100.28 Cr ₹112.66 Cr ₹113.77 Cr ₹96.83 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹200 Cr ₹150.62 Cr ₹133.33 Cr ₹76.6 Cr ₹11.61 Cr ₹143.26 Cr ₹124.6 Cr ₹120.02 Cr ₹100.28 Cr ₹112.66 Cr ₹113.77 Cr ₹96.83 Cr
Total Tax Expense ₹50.97 Cr ₹36.93 Cr ₹34.2 Cr ₹18.4 Cr ₹2.54 Cr ₹38.19 Cr ₹26.84 Cr ₹30.95 Cr ₹22.63 Cr ₹29.69 Cr ₹29.92 Cr ₹26.39 Cr
Net Profit ₹149.03 Cr ₹113.69 Cr ₹99.14 Cr ₹58.2 Cr ₹9.07 Cr ₹105.07 Cr ₹97.76 Cr ₹89.07 Cr ₹77.64 Cr ₹82.97 Cr ₹83.85 Cr ₹70.44 Cr
  attributable to Owners ₹148.13 Cr ₹113.2 Cr ₹98.25 Cr ₹58.32 Cr ₹0 ₹104.56 Cr ₹96.72 Cr ₹88.75 Cr ₹72.66 Cr ₹83.24 Cr ₹83.52 Cr ₹68.66 Cr
  attributable to NCI ₹90.3 Lakh ₹48.8 Lakh ₹88.9 Lakh -₹11.5 Lakh ₹0 ₹50.4 Lakh ₹1.04 Cr ₹31.5 Lakh -₹1.59 Cr -₹27 Lakh ₹33.2 Lakh ₹1.78 Cr
Other Comprehensive Income ₹53.94 Cr ₹19.21 Cr ₹36.47 Cr ₹66.53 Cr ₹2.65 Cr -₹38.01 Cr ₹56.6 Cr ₹2.97 Cr -₹6.58 Cr ₹34.86 Cr -₹16.48 Cr ₹16.79 Cr
Total Comprehensive Income ₹202.97 Cr ₹132.9 Cr ₹135.61 Cr ₹124.73 Cr ₹11.72 Cr ₹67.06 Cr ₹154.36 Cr ₹92.04 Cr ₹71.07 Cr ₹117.83 Cr ₹67.37 Cr ₹87.23 Cr
EBITDA (computed) ₹230.6 Cr ₹180.89 Cr ₹166.07 Cr ₹105.76 Cr ₹14.23 Cr ₹166.61 Cr ₹146.74 Cr ₹143.39 Cr ₹126.17 Cr ₹137.82 Cr ₹132.95 Cr ₹112.06 Cr
Basic EPS ₹3.27 ₹2.50 ₹2.17 ₹1.29 ₹2.00 ₹2.31 ₹2.13 ₹1.96 ₹1.73 ₹1.84 ₹1.84 ₹1.52
Diluted EPS ₹3.27 ₹2.50 ₹2.17 ₹1.29 ₹2.00 ₹2.31 ₹2.13 ₹1.96 ₹1.73 ₹1.84 ₹1.84 ₹1.52
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹1,341.48 Cr ₹1,174.37 Cr ₹853.27 Cr ₹655.2 Cr ₹658.29 Cr ₹599.55 Cr ₹433.42 Cr
Other Income ₹103.53 Cr ₹69.83 Cr ₹62.07 Cr ₹60.48 Cr ₹42.25 Cr ₹31.16 Cr ₹17.3 Lakh
Total Income ₹1,445.01 Cr ₹1,244.21 Cr ₹915.35 Cr ₹715.69 Cr ₹700.54 Cr ₹630.7 Cr ₹433.59 Cr
Cost of Materials Consumed ₹602.43 Cr ₹537.18 Cr ₹407.15 Cr ₹338.49 Cr ₹327.99 Cr ₹291.29 Cr ₹209.2 Cr
Purchases of Stock-in-Trade ₹73.06 Cr ₹102.06 Cr ₹79.03 Cr ₹66.15 Cr ₹45.71 Cr ₹46.07 Cr ₹39.46 Cr
Changes in Inventories ₹3.3 Cr ₹69.8 Lakh -₹7.25 Cr -₹10.19 Cr ₹3.89 Cr ₹55.4 Lakh -₹5.63 Cr
Employee Benefit Expense ₹121.98 Cr ₹101.68 Cr ₹77.19 Cr ₹56.09 Cr ₹60.46 Cr ₹54.64 Cr ₹48.51 Cr
Finance Costs ₹1.33 Cr ₹1.17 Cr ₹98.8 Lakh ₹3.61 Cr ₹3.8 Cr ₹5.35 Cr ₹7.29 Cr
Depreciation & Amortisation ₹34.23 Cr ₹29.45 Cr ₹29.13 Cr ₹16.74 Cr ₹17.66 Cr ₹15.19 Cr ₹11.64 Cr
Other Expenses ₹217.15 Cr ₹228.71 Cr ₹157.21 Cr ₹112.76 Cr ₹106.52 Cr ₹93.28 Cr ₹70.39 Cr
Total Expenses ₹1,053.47 Cr ₹1,000.95 Cr ₹743.45 Cr ₹583.65 Cr ₹566.03 Cr ₹506.37 Cr ₹380.86 Cr
Profit Before Exceptional Items & Tax ₹391.54 Cr ₹243.26 Cr ₹171.89 Cr ₹132.04 Cr ₹134.51 Cr ₹124.33 Cr ₹52.73 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹391.54 Cr ₹243.26 Cr ₹171.89 Cr ₹132.04 Cr ₹134.51 Cr ₹124.33 Cr ₹52.73 Cr
Total Tax Expense ₹90.85 Cr ₹54.99 Cr ₹38.13 Cr ₹29.17 Cr ₹30.52 Cr ₹25.95 Cr ₹14.82 Cr
Net Profit ₹300.7 Cr ₹188.27 Cr ₹133.76 Cr ₹102.87 Cr ₹103.99 Cr ₹98.38 Cr ₹37.9 Cr
Other Comprehensive Income ₹1.04 Cr -₹30.1 Lakh ₹28.4 Lakh -₹59.1 Lakh ₹4.6 Lakh -₹19.6 Lakh ₹16.3 Lakh
Total Comprehensive Income ₹301.74 Cr ₹187.97 Cr ₹134.04 Cr ₹102.28 Cr ₹104.03 Cr ₹98.19 Cr ₹38.07 Cr
EBITDA (computed) ₹427.1 Cr ₹273.89 Cr ₹202.01 Cr ₹152.39 Cr ₹155.97 Cr ₹144.87 Cr ₹71.66 Cr
Basic EPS ₹6.64 ₹4.15 ₹2.95 ₹2.48 ₹2.54 ₹2.40 ₹0.93
Diluted EPS ₹6.63 ₹4.15 ₹2.95 ₹2.48 ₹2.54 ₹2.40 ₹0.93
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹1,994.03 Cr ₹1,755.3 Cr ₹1,516.04 Cr ₹1,344.86 Cr
Non-current Assets ₹684.95 Cr ₹673.08 Cr ₹568.33 Cr ₹431.1 Cr
Current Assets ₹1,309.08 Cr ₹1,082.22 Cr ₹947.7 Cr ₹913.76 Cr
Property, Plant & Equipment ₹368.68 Cr ₹353.59 Cr ₹268.51 Cr ₹140.88 Cr
Inventories ₹189.13 Cr ₹205.21 Cr ₹190.85 Cr ₹130.95 Cr
Trade Receivables ₹623.46 Cr ₹549.58 Cr ₹370.17 Cr ₹305.49 Cr
Cash & Equivalents ₹91.25 Cr ₹60.27 Cr ₹41.93 Cr ₹148.31 Cr
Equity (Net Worth) ₹1,652.31 Cr ₹1,383.49 Cr ₹1,222.71 Cr ₹1,111.32 Cr
Equity Share Capital ₹45.32 Cr ₹45.32 Cr ₹45.32 Cr ₹45.32 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹310.25 Cr ₹345.64 Cr ₹272.44 Cr ₹216.54 Cr
Total Liabilities ₹341.72 Cr ₹371.82 Cr ₹293.33 Cr ₹233.54 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹211.09 Cr ₹31.02 Cr ₹34.05 Cr ₹51.73 Cr ₹50.97 Cr
Investing Cash Flow -₹140.29 Cr ₹17.24 Cr -₹114.22 Cr -₹194.62 Cr -₹8.4 Cr
Financing Cash Flow -₹39.23 Cr -₹29.92 Cr -₹26.22 Cr ₹210.02 Cr ₹75.86 Cr
Capital Expenditure ₹48.78 Cr ₹119.91 Cr ₹155.67 Cr ₹35.28 Cr ₹22.85 Cr
Free Cash Flow (computed) ₹162.31 Cr -₹88.89 Cr -₹121.62 Cr ₹16.45 Cr ₹28.12 Cr
Dividends Paid ₹36.25 Cr ₹27.19 Cr ₹22.66 Cr ₹10.17 Cr ₹10.58 Cr
Net Change in Cash ₹30.98 Cr ₹18.34 Cr -₹106.38 Cr ₹67.12 Cr ₹118.44 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹361.57 Cr ₹339.73 Cr ₹320.44 Cr ₹319.73 Cr ₹299.36 Cr ₹311.87 Cr ₹308.63 Cr ₹254.53 Cr ₹225.2 Cr ₹241.36 Cr ₹204.67 Cr ₹182.04 Cr
Other Income ₹27.48 Cr ₹15.86 Cr ₹58.19 Cr ₹2.01 Cr ₹7.82 Cr ₹22.51 Cr ₹31.36 Cr ₹8.15 Cr ₹12.19 Cr ₹1.33 Cr ₹15.93 Cr ₹32.62 Cr
Total Income ₹389.05 Cr ₹355.59 Cr ₹378.63 Cr ₹321.74 Cr ₹307.17 Cr ₹334.37 Cr ₹339.98 Cr ₹262.68 Cr ₹237.39 Cr ₹242.69 Cr ₹220.6 Cr ₹214.66 Cr
Cost of Materials Consumed ₹159.48 Cr ₹151 Cr ₹146.66 Cr ₹145.28 Cr ₹145.06 Cr ₹141.27 Cr ₹134.73 Cr ₹116.12 Cr ₹104.36 Cr ₹117.16 Cr ₹102.83 Cr ₹82.8 Cr
Purchases of Stock-in-Trade ₹13.26 Cr ₹16.02 Cr ₹20.99 Cr ₹22.8 Cr ₹16.77 Cr ₹23.33 Cr ₹30.97 Cr ₹30.99 Cr ₹20.39 Cr ₹22.12 Cr ₹17.56 Cr ₹18.97 Cr
Changes in Inventories ₹2.58 Cr ₹6.18 Cr -₹2.17 Cr -₹3.29 Cr ₹2.3 Cr ₹5.63 Cr -₹54.6 Lakh -₹6.69 Cr -₹2.13 Cr -₹1.46 Cr -₹5.9 Cr ₹2.25 Cr
Employee Benefit Expense ₹32.92 Cr ₹32.7 Cr ₹28.46 Cr ₹27.9 Cr ₹28.82 Cr ₹25.75 Cr ₹23.91 Cr ₹23.19 Cr ₹21.56 Cr ₹20.47 Cr ₹18.23 Cr ₹16.93 Cr
Finance Costs ₹35.3 Lakh ₹35.7 Lakh ₹31.5 Lakh ₹30.2 Lakh ₹31.1 Lakh ₹30.4 Lakh ₹27.6 Lakh ₹28.3 Lakh ₹22.8 Lakh ₹26.7 Lakh ₹23.1 Lakh ₹26.2 Lakh
Depreciation & Amortisation ₹8.76 Cr ₹8.83 Cr ₹8.46 Cr ₹8.19 Cr ₹8.18 Cr ₹7.42 Cr ₹7.02 Cr ₹6.84 Cr ₹7.47 Cr ₹8.43 Cr ₹8.5 Cr ₹4.72 Cr
Other Expenses ₹47.34 Cr ₹58.38 Cr ₹54.43 Cr ₹56.99 Cr ₹55.84 Cr ₹55.94 Cr ₹67.29 Cr ₹49.65 Cr ₹47.11 Cr ₹41.11 Cr ₹34.65 Cr ₹34.35 Cr
Total Expenses ₹264.69 Cr ₹273.47 Cr ₹257.14 Cr ₹258.17 Cr ₹257.27 Cr ₹259.65 Cr ₹263.65 Cr ₹220.38 Cr ₹198.99 Cr ₹208.09 Cr ₹176.1 Cr ₹160.27 Cr
Profit Before Exceptional Items & Tax ₹124.36 Cr ₹82.12 Cr ₹121.49 Cr ₹63.57 Cr ₹49.9 Cr ₹74.72 Cr ₹76.34 Cr ₹42.3 Cr ₹38.4 Cr ₹34.6 Cr ₹44.5 Cr ₹54.4 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹124.36 Cr ₹82.12 Cr ₹121.49 Cr ₹63.57 Cr ₹49.9 Cr ₹74.72 Cr ₹76.34 Cr ₹42.3 Cr ₹38.4 Cr ₹34.6 Cr ₹44.5 Cr ₹54.4 Cr
Total Tax Expense ₹32.44 Cr ₹21.2 Cr ₹21.69 Cr ₹15.52 Cr ₹12.31 Cr ₹19.26 Cr ₹13.13 Cr ₹10.28 Cr ₹5.41 Cr ₹9.31 Cr ₹13.21 Cr ₹10.2 Cr
Net Profit ₹91.92 Cr ₹60.91 Cr ₹99.81 Cr ₹48.06 Cr ₹37.59 Cr ₹55.46 Cr ₹63.2 Cr ₹32.02 Cr ₹32.99 Cr ₹25.29 Cr ₹31.29 Cr ₹44.19 Cr
Other Comprehensive Income ₹25.7 Lakh ₹93.4 Lakh -₹7.4 Lakh -₹7.6 Lakh -₹51.3 Lakh ₹7.1 Lakh ₹7 Lakh ₹7.1 Lakh ₹77.2 Lakh -₹16.2 Lakh -₹16.3 Lakh -₹16.2 Lakh
Total Comprehensive Income ₹92.18 Cr ₹61.85 Cr ₹99.73 Cr ₹47.98 Cr ₹37.08 Cr ₹55.53 Cr ₹63.27 Cr ₹32.09 Cr ₹33.77 Cr ₹25.13 Cr ₹31.13 Cr ₹44.03 Cr
EBITDA (computed) ₹133.47 Cr ₹91.3 Cr ₹130.26 Cr ₹72.06 Cr ₹58.39 Cr ₹82.45 Cr ₹83.63 Cr ₹49.42 Cr ₹46.1 Cr ₹43.3 Cr ₹53.23 Cr ₹59.38 Cr
Basic EPS ₹2.03 ₹1.34 ₹2.20 ₹1.06 ₹0.83 ₹1.22 ₹1.39 ₹0.71 ₹0.73 ₹0.56 ₹0.69 ₹0.98
Diluted EPS ₹2.03 ₹1.34 ₹2.20 ₹1.06 ₹0.83 ₹1.22 ₹1.39 ₹0.71 ₹0.73 ₹0.56 ₹0.69 ₹0.98
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Marksans Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Marksans Pharma Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 43.87%, foreign institutional investors hold 16.76%, domestic institutional investors hold 6.57%, retail and other public shareholders hold 32.79% of Marksans Pharma Limited. The company had 246,279 shareholders on record.

Promoters: 43.87%DII (Domestic Institutional): 6.57%FII (Foreign Institutional): 16.76%Retail & Others: 32.79%
Mar 2026
QUARTER
43.87% Promoters
6.57% DII (Domestic Institutional)
16.76% FII (Foreign Institutional)
32.79% Retail & Others
Promoter holding - history
Now 43.87% · Mar 2026High 49.00% · Dec 2022Low 43.80% · Jan 2023
42%44%46%48%50%Dec 2015Jun 2018Dec 2020Mar 2023Sep 2025Dec 2015: 48.25%Mar 2016: 48.25%Jun 2016: 48.25%Sep 2016: 48.25%Dec 2016: 48.25%Mar 2017: 48.25%Jun 2017: 48.25%Sep 2017: 48.25%Dec 2017: 48.25%Mar 2018: 48.25%Jun 2018: 48.25%Sep 2018: 48.25%Dec 2018: 48.25%Mar 2019: 48.25%Jun 2019: 48.25%Sep 2019: 48.25%Dec 2019: 48.25%Mar 2020: 48.25%Jun 2020: 48.25%Sep 2020: 48.25%Dec 2020: 48.25%Mar 2021: 48.25%Jun 2021: 48.25%Sep 2021: 48.25%Dec 2021: 48.25%Mar 2022: 48.25%Jun 2022: 48.25%Sep 2022: 48.60%Dec 2022: 49.00%Jan 2023: 43.80%Mar 2023: 43.85%Jun 2023: 43.85%Sep 2023: 43.85%Dec 2023: 43.85%Mar 2024: 43.85%Jun 2024: 43.87%Sep 2024: 43.87%Dec 2024: 43.87%Mar 2025: 43.87%Jun 2025: 43.87%Sep 2025: 43.87%Dec 2025: 43.87%Mar 2026: 43.87%49.00%43.80%43.87%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters43.87%43.87%43.87%43.87%43.87%43.87%
Public56.13%56.13%56.13%56.13%56.13%56.13%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters43.87%43.87%43.85%43.85%48.25%48.25%48.25%48.25%48.25%48.25%48.25%
Public56.13%56.13%56.15%56.15%51.75%51.75%51.74%51.75%51.75%51.75%51.75%
Promoter change (YoY, %pts)+0.00+0.02+0.00-4.40+0.00+0.00+0.00+0.00+0.00+0.00-

Board & Governance of Marksans Pharma Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Marksans Pharma Limited has 8 directors - 4 independent and 3 executive. The board is chaired by MARK SALDANHA.

DirectorPositionOn board sinceListed boards
MARK SALDANHA Executive Director · CEO-MD · Chairperson 2005-10-06 1
SANDRA SALDANHA Executive Director 2014-09-25 1
VARDDHMAN VIKRAMADITYA JAIN Executive Director 2019-01-24 1
DIGANT MAHESH PARIKH Non-Executive - Independent Director 2018-03-14 1
ABHINNA SUNDAR MOHANTY Non-Executive - Independent Director 2019-07-11 1
SHAILAJA VARDHAN Non-Executive - Independent Director 2023-05-30 1
SUNNY SHARMA Non-Executive - Non Independent Director 2021-08-11 2
SRINIVAS MISHRA Non-Executive - Independent Director 2025-04-01 1
Board Committees
CommitteeMembers
Audit Committee DIGANT MAHESH PARIKH (Chairperson), SUNNY SHARMA, ABHINNA SUNDAR MOHANTY
Nomination and remuneration committee ABHINNA SUNDAR MOHANTY (Chairperson), DIGANT MAHESH PARIKH, SUNNY SHARMA
Stakeholders Relationship Committee ABHINNA SUNDAR MOHANTY (Chairperson), DIGANT MAHESH PARIKH, VARDDHMAN VIKRAMADITYA JAIN
Risk Management Committee VARDDHMAN VIKRAMADITYA JAIN (Chairperson), JITENDRA SHARMA, ABHINNA SUNDAR MOHANTY
Corporate Social Responsibility Committee VARDDHMAN VIKRAMADITYA JAIN (Chairperson), SANDRA SALDANHA, ABHINNA SUNDAR MOHANTY

Charges & Borrowings of Marksans Pharma Limited

Open charges
₹226 Cr
Satisfied charges
₹337.16 Cr
Breakdown by lending institutions
State Bank of India₹226.00 Cr
Latest charge details
DateLenderAmountStatus
07 Feb 2006 State Bank of India ₹226 Cr Open
07 Sep 2017 State Bank of India ₹66.8 Cr Satisfied
23 Jun 2015 State Bank of India ₹44.41 Cr Satisfied
23 Dec 2013 Bank of India ₹4 Cr Satisfied
13 Aug 2010 Bank of India ₹6 Cr Satisfied

Total charge records: 26 View all charges

Employees and EPFO Compliance at Marksans Pharma Limited

Marksans Pharma Limited has a workforce of 95 employees as of Apr 08, 2024.

Employee count
95
Active EPFO establishments
1
Employee growth
13.1%
Premium access

Employee and EPFO history for Marksans Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Marksans Pharma Limited

Premium access

GST registrations and filing compliance for Marksans Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Marksans Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Marksans Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Marksans Pharma Limited

Premium access

MSME payment history for Marksans Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Marksans Pharma Limited

Premium access

Corporate group structure for Marksans Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Marksans Pharma Limited

Premium access

MCA filings and documents for Marksans Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Marksans Pharma Limited

Activity
08 Aug 2025
Marksans Pharma Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records.
Directors
01 Apr 2025
Srinivas Mishra was appointed as a Director on 01 Apr 2025 & has been associated with this company since 1 year 4 months.
Activity
31 Mar 2025
Marksans Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
03 Feb 2025
A charge with State Bank Of India of Rs. 226.00 Cr registered on 07 Feb 2006 with Charge ID 80034914 was modified on 03 Feb 2025.
Directors
30 May 2023
Shailaja Vardhan was appointed as a Director on 30 May 2023 & has been associated with this company since 3 years 2 months.
Charges
29 Oct 2021
A charge registered on 07 Sep 2017 via Charge ID 100125187 with State Bank Of India was fully satisfied on 29 Oct 2021.

Recent News on Marksans Pharma Limited

Frequently Asked Questions about Marksans Pharma Limited

Marksans Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 16 April 1992 (34+ years old) and is registered under CIN L24110MH1992PLC066364. Listed on BSE: 524404 and NSE: MARKSANS. The company has 95 employees.

Marksans Pharma Limited reported revenue of ₹2,950.94 Cr for FY 2026 (up 1025.09% YoY) based on consolidated NSE filings.

The current directors of Marksans Pharma Limited are:

The primary industry of Marksans Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Marksans Pharma Limited is listed on both BSE (code: 524404) and NSE (symbol: MARKSANS).

Marksans Pharma Limited can be reached at the registered office: 11Th Floor Grandeur Veera Desai Extension Road Oshiwara Andheri W, Mumbai, Maharashtra, India – 400053, or through the website marksanspharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available